靶向CD54的免疫PET显像在实体瘤中的开发与表征
本研究以64Cu标记ICAM-1(CD54)特异性单克隆抗体R6-5-D6,构建靶向ICAM-1的免疫PET探针,在黑色素瘤A375与未分化甲状腺癌THJ-16T荷瘤小鼠模型中评估显像效果。结果显示A375黑色素瘤峰值摄取21.28 ± 6.56 %ID/g(n = 5),显著高于64Cu-NOTA-IgG的10.63 ± 2.58 %ID/g(n = 3),并可清晰显示皮下与原位未分化甲状腺癌。
要点
- 64Cu-NOTA-ICAM-1免疫PET可清晰显示A375黑色素瘤,峰值肿瘤摄取21.28 ± 6.56 %ID/g(n = 5)。
- 该探针肿瘤摄取显著高于64Cu-NOTA-IgG的10.63 ± 2.58 %ID/g(n = 3)。
- 免疫PET可清晰显示皮下与原位未分化甲状腺癌,荧光显像可被R6-5-D6阻断。
核心结论
- 靶向ICAM-1的免疫PET显像可表征黑色素瘤与未分化甲状腺癌中的ICAM-1表达,作者认为其有望用于未来优化ICAM-1靶向治疗。
研究设计与样本
- 研究采用流式细胞术筛选ICAM-1阳性的黑色素瘤与未分化甲状腺癌细胞系。
- 分别用A375细胞系建立黑色素瘤模型、THJ-16T细胞系建立未分化甲状腺癌模型。
- 将ICAM-1特异性单克隆抗体R6-5-D6与非特异性人IgG用64Cu标记,在荷瘤小鼠模型中评估诊断效能。
- 进行生物分布与荧光显像研究以确认ICAM-1靶向探针的特异性。
主要发现
- ICAM-1在黑色素瘤与晚期甲状腺癌细胞系上强表达。
- 64Cu-NOTA-ICAM-1免疫PET清晰勾画A375黑色素瘤,峰值肿瘤摄取21.28 ± 6.56 %ID/g(n = 5),显著高于64Cu-NOTA-IgG的10.63 ± 2.58 %ID/g(n = 3)。
- 64Cu-NOTA-ICAM-1免疫PET以高清晰度与对比度有效显示皮下与原位未分化甲状腺癌。
- IRDye 800CW-ICAM-1荧光显像可显示原位未分化甲状腺癌,且肿瘤摄取可被ICAM-1母体抗体R6-5-D6阻断,提示探针特异性高。
- 在人IgG阻断下,64Cu-NOTA-ICAM-1在R2G2小鼠中的循环时间延长,而肿瘤摄取未受影响。
关键数值与推荐
- A375黑色素瘤峰值肿瘤摄取:64Cu-NOTA-ICAM-1为21.28 ± 6.56 %ID/g(n = 5),64Cu-NOTA-IgG为10.63 ± 2.58 %ID/g(n = 3)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Intercellular adhesion molecule-1 (ICAM-1, CD54) is an emerging therapeutic target for a variety of solid tumors including melanoma and anaplastic thyroid cancer (ATC). This study aims to develop an ICAM-1-targeted immuno-positron emission tomography (immunoPET) imaging strategy and assess its diagnostic value in melanoma and ATC models. METHODS: Flow cytometry was used to screen ICAM-1-positive melanoma and ATC cell lines. Melanoma and ATC models were established using A375 cell line and THJ-16T cell line, respectively. An ICAM-1-specific monoclonal antibody (R6-5-D6) and a nonspecific human IgG were radiolabeled with 64Cu and the diagnostic efficacies were interrogated in tumor-bearing mouse models. Biodistribution and fluorescent imaging studies were performed to confirm the specificity of the ICAM-1-targeted imaging probes. RESULTS: ICAM-1 was strongly expressed on melanoma and advanced thyroid cancer cell lines. 64Cu-NOTA-ICAM-1 immunoPET imaging efficiently delineated A375 melanomas with a peak tumor uptake of 21.28 ± 6.56 %ID/g (n = 5), significantly higher than that of 64Cu-NOTA-IgG (10.63 ± 2.58 %ID/g, n = 3). Moreover, immunoPET imaging with 64Cu-NOTA-ICAM-1 efficiently visualized subcutaneous and orthotopic ATCs with high clarity and contrast. Fluorescent imaging with IRDye 800CW-ICAM-1 also visualized orthotopic ATCs and the tumor uptake could be blocked by the ICAM-1 parental antibody R6-5-D6, indicating the high specificity of the developed probe. Finally, blocking with the human IgG prolonged the circulation of the 64Cu-NOTA-ICAM-1 in R2G2 mice without compromising the tumor uptake. CONCLUSION: ICAM-1-targeted immunoPET imaging could characterize ICAM-1 expression in melanoma and ATC, which holds promise for optimizing ICAM-1-targeted therapies in the future.
引用
- Wei W, Jiang D, Lee HJ, et al. Development and characterization of CD54-targeted immunoPET imaging in solid tumors. Eur J Nucl Med Mol Imaging. 2020. PMID: 32279097. doi:10.1007/s00259-020-04784-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。